ClearPoint Neuro, Inc.

ClearPoint Neuro, Inc. (NASDAQ:CLPT) is a medical device company founded in 1998 and headquartered in Solana Beach, California. Originally incorporated as MRI Interventions, Inc., the company changed its name to ClearPoint Neuro in February 2020 to better reflect its focus on neurological applications. The company specializes in developing and commercializing platforms that enable minimally invasive surgical procedures in the brain under direct, real-time magnetic resonance imaging (MRI) guidance. ClearPoint has established itself as a key enabler in the emerging cell and gene therapy market while also serving traditional neurosurgery applications.

Over the past few years, ClearPoint Neuro has undergone significant strategic evolution, transitioning from a traditional neurosurgery navigation company to a key enabler of the emerging cell and gene therapy market. The company launched its "Fast Forward" strategic phase in 2024, focusing on three core pillars: extending its lead in cell and gene therapy delivery, evolving its product portfolio for simpler workflows, and expanding its global installed base. Product Innovation and Regulatory Achievements: The company achieved a major milestone with the FDA approval of PTC Therapeutics' Upstaza gene therapy, which uses ClearPoint's co-labeled SmartFlow cannula - marking the first approved gene therapy utilizing the company's technology. Building on this success, ClearPoint submitted a 510(k) application for its SmartFlow cannula specifically for REGENXBIO's gene therapy program and launched its ClearPoint 3.0 navigation software, which enables procedures in traditional operating rooms rather than requiring MRI suites. Market Expansion and Partnerships: The company has dramatically expanded its pharmaceutical partnerships from around 50 to over 60 active biopharma partners, with seven partnered programs designated for FDA accelerated pathways. ClearPoint activated 19 new customer sites in 2024 and now operates more than 100 activated centers worldwide. The company is targeting 150-300 hospitals globally and expects 15-20 new site activations in 2025. Operational Infrastructure Development: ClearPoint completed the transition to its new 20,000 square foot manufacturing facility in Carlsbad, California, and is preparing for GLP (Good Laboratory Practice) certification in the second half of 2025. This will enable the company to conduct preclinical studies required for regulatory approval, representing a significant expansion of its service capabilities. The company has also been aggressively hiring preclinical and field support teams to support anticipated growth in gene therapy approvals. Financial and Strategic Positioning: The company secured $32 million in funding from Oberland Capital, providing additional runway for growth investments. ClearPoint has also implemented new business models, including the Pathfinder subscription program and various partnership structures ranging from co-development agreements to milestone payments and royalty arrangements, creating multiple revenue streams from its pharmaceutical partnerships.